Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
18 results
D1.472 - Features of the intestinal microbiota composition in infants with allergy: comparison of two diagnostic methods
D1.473 - Features of the intestinal microbiota composition in infants with IgE- and non-IgE-mediated allergy
D1.476 - Impact of neonatal vaccination on the incidence of atopic dermatitis in children by 36 months: a prospective cohort study
D1.480 - Polysomnographic phenotypes of sleep-disordered breathing in children with asthma: a systematic review
D1.467 - Economic Burden of Allergic Diseases in Children: Global Evidence and Implications for Kyrgyzstan
D1.475 - Significance of air-trapping and pulmonary hyperinflation in the severity of broncho-obstructive manifestations in children with cystic fibrosis
D1.478 - Hyper-IgE in allergic bronchopulmonary aspergillosis: diagnostic challenges
D1.479 - Lung function in children with cystic fibrosis associated with wheezing
D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?
D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025
D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing
D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity
D2.29 - Use and knowledge of Phadiatop Infant and Fx5 in children from a primary care healthcare area
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut
D3.448 - Use of Sebetralstat as Short-term Prophylaxis for Patients with Hereditary Angioedema: Results from the KONFIDENT-S Study
Download the app
The congress at your fingertips
Available on
Download